GSK plc (LON:GSK - Get Free Report) shares crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 1,440 ($18.60) and traded as high as GBX 1,522.50 ($19.66). GSK shares last traded at GBX 1,511 ($19.51), with a volume of 9,054,711 shares changing hands.
Wall Street Analysts Forecast Growth
GSK has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a research report on Tuesday, January 7th. Berenberg Bank reduced their target price on GSK from GBX 1,820 ($23.50) to GBX 1,600 ($20.66) and set a "buy" rating for the company in a report on Friday, November 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of GBX 1,805.83 ($23.32).
Check Out Our Latest Stock Report on GSK
GSK Trading Down 1.6 %
The firm has a 50 day moving average of GBX 1,441.42 and a 200 day moving average of GBX 1,437.45. The firm has a market cap of £60.26 billion, a PE ratio of 23.99, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64.
GSK (LON:GSK - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Equities analysts anticipate that GSK plc will post 175.980975 earnings per share for the current year.
Insider Activity at GSK
In related news, insider Emma Walmsley sold 120,653 shares of the business's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of GBX 1,453 ($18.76), for a total transaction of £1,753,088.09 ($2,263,801.77). Also, insider Wendy Becker purchased 536 shares of the stock in a transaction on Thursday, March 20th. The stock was acquired at an average cost of GBX 1,515 ($19.56) per share, for a total transaction of £8,120.40 ($10,486.05). 1.61% of the stock is currently owned by corporate insiders.
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Stories
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
